Denali Therapeutics Inc.
DNLI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
In the last 90 days, Denali Therapeutics Inc. insiders filed 0 open-market purchases and 4 sales; 294 institutions reported holding it in 13F filings for Q2 2026, worth $4.00B in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Denali Therapeutics Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 200 | 199 | −1 |
| Shares | 92.4M | 105.9M | +13.5M (+14.6%) |
| Value | $2.84B | $2.94B | +$108.6M (+3.8%) |
New holders (27)
Institutions that held Denali Therapeutics Inc. at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (28)
Institutions that held Denali Therapeutics Inc. at the end of Q3 2022 and filed for Q4 2022 without it.